United Therapeutics CORP Form 4 insider transactions

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 30 and 31, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 28 and 29, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Director Martine Rothblatt exercised stock options and sold shares of United Therapeutics Corp (UTHR) on May 22, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 20 and May 21, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Christopher Causey exercised stock options and sold 2,000 shares of United Therapeutics Corp (UTHR) on May 15, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics Corp, reports the acquisition and disposal of common stock and share tracking awards on May 15, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 14 and 15, 2024, under a pre-arranged 10b5-1 trading plan.

Christopher Patusky, a director at United Therapeutics Corp, exercised stock options and sold shares on May 14, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 10 and May 13, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 7, 2024, under a pre-arranged 10b5-1 trading plan.

Michael Benkowitz, COO of United Therapeutics, exercised share tracking awards and disposed of common stock on May 6, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 3rd and 6th, 2024, under a pre-arranged 10b5-1 trading plan.

Director Christopher Causey exercised stock options and sold shares of United Therapeutics Corp on May 3, 2024.

Director Judy D. Olian exercised stock options and sold shares of United Therapeutics Corp (UTHR) on May 3, 2024.

Director Louis W. Sullivan exercised stock options and sold shares of United Therapeutics Corp on May 3, 2024.

Martine Rothblatt, CEO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on April 29 and 30, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 25 and 26, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised share tracking awards of United Therapeutics Corporation under a pre-arranged Rule 10b5-1 trading plan, resulting in cash settlement.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised share tracking awards of United Therapeutics Corporation under a pre-arranged Rule 10b5-1 trading plan.